Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.43 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL368609 | 1.00 | PTGS2 (0.43) | PTGS2SOAT1FAAH | |
| SCHEMBL11467737 | 0.79 | CXCL8 (0.49) | — | |
| SCHEMBL341491 | 0.79 | SOAT1 (0.46) | SOAT1 | |
| SCHEMBL338541 | 0.78 | MAPT (0.43) | PTGS2SOAT1 | |
| SCHEMBL339362 | 0.76 | CXCL8 (0.46) | PTGS2 | |
| SCHEMBL1926388 | 0.76 | KCNA3 (0.48) | SOAT1 | |
| SCHEMBL27782837 | 0.75 | PTGER1 (0.49) | SOAT1 | |
| SCHEMBL341017 | 0.75 | KMT2A (0.45) | PTGS2 | |
| SCHEMBL4785901 | 0.73 | BCAT2 (0.51) | SOAT1 | |
| SCHEMBL2393839 | 0.73 | PTGS2 (0.56) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2890672-B1 | PROCESSES FOR PREPARING INTERMEDIATES FOR THE MANUFACTURE OF NEP INHIBITORS | NOVARTIS AG (CH) | 2018-05-30 | — | — | EP | disclosed |
| US-9624163-B2 | Process for preparing intermediates useful in the manufacture of NEP inhibitors | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| US-20150210632-A1 | NEW PROCESS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| EP-2890672-A1 | NEW PROCESS | Novartis AG (CH) | 2015-07-08 | — | — | EP | disclosed |
| WO-2014032627-A1 | NEW PROCESS | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD (CN) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210632-A1 | NEW PROCESS | MME, DNPEP, ACE | PTGS2 2089/4885SOAT1 2398/4885FAAH 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.